Pharmafile Logo

LMTX

- PMLiVE

Independent analysis raises hope for Lilly’s Alzheimer’s drug

Pooled results show solanezumab slowed cognitive decline in subgroup by 34 per cent

FDA sued for approving high dose of Eisai’s Alzheimer’s drug Aricept

Consumer rights group Public Citizen claims the high-strength dose is unsafe

- PMLiVE

Lilly’s Alzheimer’s drug solanezumab stumbles, but doesn’t fall in phase III

Fails to show significant benefit, but data holds some consolation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links